Hemolytic disease of the fetus and newborn in the sensitizing pregnancy where anti‐D was incorrectly identified as RhIG
Background Hemolytic disease of the fetus and newborn (HDFN) is a potentially fatal complication in Rh‐incompatible pregnancies and rarely occurs in the sensitizing pregnancy. Distinguishing RhIG from true anti‐D identified is challenging. A case of severe HDFN in which a sample drawn at 28 weeks sh...
Saved in:
Published in | Journal of clinical laboratory analysis Vol. 36; no. 4; pp. e24323 - n/a |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
United States
John Wiley & Sons, Inc
01.04.2022
John Wiley and Sons Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background
Hemolytic disease of the fetus and newborn (HDFN) is a potentially fatal complication in Rh‐incompatible pregnancies and rarely occurs in the sensitizing pregnancy. Distinguishing RhIG from true anti‐D identified is challenging. A case of severe HDFN in which a sample drawn at 28 weeks showed anti‐D antibody (3+ strength) attributed to RhIG is described. RBC antibody testing early in pregnancy was negative. At birth, the infant was severely anemic and maternal anti‐D titer was 1:256. This case represents a clinically significant anti‐D in the sensitizing pregnancy that was missed due to confusion with RhIG.
Methods
To determine if agglutination strength could be helpful, a retrospective chart‐review using both electronic and paper medical records was performed on 348 samples identified as RhIG and 52 true anti‐D samples. The agglutination strength of antibody was recorded for each sample.
Results
For RhIG, there was an even distribution between the weak to moderate agglutination strength (w+, 1+, and 2+) results (35%, 26%, and 33%, respectively) and just 6% had a 3+ strength. Agglutination strength in patients with high titer (≥1:16) anti‐D showed they often (44.4%) have 1+ or 2+ agglutination reactivity.
Conclusions
These results show that agglutination strength alone does not provide reliable evidence to distinguish RhIG from high titer anti‐D antibodies. We recommend that in cases where there is any uncertainty about whether the anti‐D reactivity is due to RhIG, titers should be performed to rule out clinically significant anti‐D antibody. |
---|---|
AbstractList | BackgroundHemolytic disease of the fetus and newborn (HDFN) is a potentially fatal complication in Rh‐incompatible pregnancies and rarely occurs in the sensitizing pregnancy. Distinguishing RhIG from true anti‐D identified is challenging. A case of severe HDFN in which a sample drawn at 28 weeks showed anti‐D antibody (3+ strength) attributed to RhIG is described. RBC antibody testing early in pregnancy was negative. At birth, the infant was severely anemic and maternal anti‐D titer was 1:256. This case represents a clinically significant anti‐D in the sensitizing pregnancy that was missed due to confusion with RhIG.MethodsTo determine if agglutination strength could be helpful, a retrospective chart‐review using both electronic and paper medical records was performed on 348 samples identified as RhIG and 52 true anti‐D samples. The agglutination strength of antibody was recorded for each sample.ResultsFor RhIG, there was an even distribution between the weak to moderate agglutination strength (w+, 1+, and 2+) results (35%, 26%, and 33%, respectively) and just 6% had a 3+ strength. Agglutination strength in patients with high titer (≥1:16) anti‐D showed they often (44.4%) have 1+ or 2+ agglutination reactivity.ConclusionsThese results show that agglutination strength alone does not provide reliable evidence to distinguish RhIG from high titer anti‐D antibodies. We recommend that in cases where there is any uncertainty about whether the anti‐D reactivity is due to RhIG, titers should be performed to rule out clinically significant anti‐D antibody. Background Hemolytic disease of the fetus and newborn (HDFN) is a potentially fatal complication in Rh‐incompatible pregnancies and rarely occurs in the sensitizing pregnancy. Distinguishing RhIG from true anti‐D identified is challenging. A case of severe HDFN in which a sample drawn at 28 weeks showed anti‐D antibody (3+ strength) attributed to RhIG is described. RBC antibody testing early in pregnancy was negative. At birth, the infant was severely anemic and maternal anti‐D titer was 1:256. This case represents a clinically significant anti‐D in the sensitizing pregnancy that was missed due to confusion with RhIG. Methods To determine if agglutination strength could be helpful, a retrospective chart‐review using both electronic and paper medical records was performed on 348 samples identified as RhIG and 52 true anti‐D samples. The agglutination strength of antibody was recorded for each sample. Results For RhIG, there was an even distribution between the weak to moderate agglutination strength (w+, 1+, and 2+) results (35%, 26%, and 33%, respectively) and just 6% had a 3+ strength. Agglutination strength in patients with high titer (≥1:16) anti‐D showed they often (44.4%) have 1+ or 2+ agglutination reactivity. Conclusions These results show that agglutination strength alone does not provide reliable evidence to distinguish RhIG from high titer anti‐D antibodies. We recommend that in cases where there is any uncertainty about whether the anti‐D reactivity is due to RhIG, titers should be performed to rule out clinically significant anti‐D antibody. Abstract Background Hemolytic disease of the fetus and newborn (HDFN) is a potentially fatal complication in Rh‐incompatible pregnancies and rarely occurs in the sensitizing pregnancy. Distinguishing RhIG from true anti‐D identified is challenging. A case of severe HDFN in which a sample drawn at 28 weeks showed anti‐D antibody (3+ strength) attributed to RhIG is described. RBC antibody testing early in pregnancy was negative. At birth, the infant was severely anemic and maternal anti‐D titer was 1:256. This case represents a clinically significant anti‐D in the sensitizing pregnancy that was missed due to confusion with RhIG. Methods To determine if agglutination strength could be helpful, a retrospective chart‐review using both electronic and paper medical records was performed on 348 samples identified as RhIG and 52 true anti‐D samples. The agglutination strength of antibody was recorded for each sample. Results For RhIG, there was an even distribution between the weak to moderate agglutination strength (w+, 1+, and 2+) results (35%, 26%, and 33%, respectively) and just 6% had a 3+ strength. Agglutination strength in patients with high titer (≥1:16) anti‐D showed they often (44.4%) have 1+ or 2+ agglutination reactivity. Conclusions These results show that agglutination strength alone does not provide reliable evidence to distinguish RhIG from high titer anti‐D antibodies. We recommend that in cases where there is any uncertainty about whether the anti‐D reactivity is due to RhIG, titers should be performed to rule out clinically significant anti‐D antibody. Hemolytic disease of the fetus and newborn (HDFN) is a potentially fatal complication in Rh-incompatible pregnancies and rarely occurs in the sensitizing pregnancy. Distinguishing RhIG from true anti-D identified is challenging. A case of severe HDFN in which a sample drawn at 28 weeks showed anti-D antibody (3+ strength) attributed to RhIG is described. RBC antibody testing early in pregnancy was negative. At birth, the infant was severely anemic and maternal anti-D titer was 1:256. This case represents a clinically significant anti-D in the sensitizing pregnancy that was missed due to confusion with RhIG. To determine if agglutination strength could be helpful, a retrospective chart-review using both electronic and paper medical records was performed on 348 samples identified as RhIG and 52 true anti-D samples. The agglutination strength of antibody was recorded for each sample. For RhIG, there was an even distribution between the weak to moderate agglutination strength (w+, 1+, and 2+) results (35%, 26%, and 33%, respectively) and just 6% had a 3+ strength. Agglutination strength in patients with high titer (≥1:16) anti-D showed they often (44.4%) have 1+ or 2+ agglutination reactivity. These results show that agglutination strength alone does not provide reliable evidence to distinguish RhIG from high titer anti-D antibodies. We recommend that in cases where there is any uncertainty about whether the anti-D reactivity is due to RhIG, titers should be performed to rule out clinically significant anti-D antibody. |
Author | Leon, Judith Walhof, Mackenzie L. Greiner, Andrea L. Knudson, Charles Michael Scott, James R. |
AuthorAffiliation | 2 Department of Obstetrics and Gynecology University of Iowa Hospitals & Clinics Iowa City Iowa USA 1 DeGowin Blood Center Department of Pathology University of Iowa Hospitals & Clinics Iowa City Iowa USA |
AuthorAffiliation_xml | – name: 1 DeGowin Blood Center Department of Pathology University of Iowa Hospitals & Clinics Iowa City Iowa USA – name: 2 Department of Obstetrics and Gynecology University of Iowa Hospitals & Clinics Iowa City Iowa USA |
Author_xml | – sequence: 1 givenname: Mackenzie L. surname: Walhof fullname: Walhof, Mackenzie L. organization: University of Iowa Hospitals & Clinics – sequence: 2 givenname: Judith surname: Leon fullname: Leon, Judith organization: University of Iowa Hospitals & Clinics – sequence: 3 givenname: Andrea L. surname: Greiner fullname: Greiner, Andrea L. organization: University of Iowa Hospitals & Clinics – sequence: 4 givenname: James R. surname: Scott fullname: Scott, James R. organization: University of Iowa Hospitals & Clinics – sequence: 5 givenname: Charles Michael orcidid: 0000-0003-3964-5466 surname: Knudson fullname: Knudson, Charles Michael email: c-knudson@uiowa.edu organization: University of Iowa Hospitals & Clinics |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35243688$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc1qGzEUhUVISZy0mzxAEHRXmFQ_MxppUwhum6QYAqFdC1lzZcuMJVca10xXfYQ-Y54kSpyGdtPV5XI-zj2Xc4IOQwyA0BklF5QQ9n5le3PBas74AZpQomTFJGsO0YRI2VaSUH6MTnJeEUKkouIIHfOm4ELKCRqvYR37cfAWdz6DyYCjw8MSsINhm7EJHQ6wm8cUsA9PQoaQ_eB_-rDAmwSLYIId8W4JCQo--Ptfvz_incmFtzElsEM_Yt9BkZyHDhflbnlz9Rq9cqbP8OZ5nqJvnz99nV5Xs9urm-nlrLI1bXhVW0qd7Dg0TBrOm9pIVzbVivIAA2aAq1YJKhvVlv-cE8LNoW4d5R1rhOSn6MPed7Odr6GzJUcyvd4kvzZp1NF4_a8S_FIv4g8tleKiZsXg7bNBit-3kAe9itsUSmbNRC2Zkk3LC_VuT9kUc07gXi5Qoh9r0o816aeaCnz-d6YX9E8vBaB7YOd7GP9jpb9MZ5d70wc0_aGB |
CitedBy_id | crossref_primary_10_1016_j_transci_2024_103969 crossref_primary_10_7759_cureus_60158 crossref_primary_10_1016_j_tracli_2023_11_002 |
Cites_doi | 10.1016/j.tmrv.2018.07.002 10.1097/AOG.0b013e31817d453c 10.1016/j.tmrv.2016.05.008 10.1053/j.semperi.2011.02.009 10.1111/vox.12302 10.1136/adc.2005.076794 10.1055/s-2007-1022894 10.1046/j.1537-2995.2000.40091127.x 10.1046/j.1365-3148.1999.009001093.x 10.21307/immunohematology-2019-681 |
ContentType | Journal Article |
Copyright | 2022 The Authors. published by Wiley Periodicals LLC. 2022 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC. 2022. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: 2022 The Authors. published by Wiley Periodicals LLC. – notice: 2022 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC. – notice: 2022. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | 24P WIN CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7QP 7T5 7U9 7X7 7XB 8C1 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M7P PIMPY PQEST PQQKQ PQUKI PRINS 5PM |
DOI | 10.1002/jcla.24323 |
DatabaseName | Wiley Online Library Open Access Wiley Online Library Free Content Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Immunology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) Biological Science Database Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Public Health Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest Central (Alumni) |
DatabaseTitleList | Publicly Available Content Database CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | WALHOF et al |
EISSN | 1098-2825 |
EndPage | n/a |
ExternalDocumentID | 10_1002_jcla_24323 35243688 JCLA24323 |
Genre | caseStudy Case Reports |
GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 24P 31~ 33P 3SF 3WU 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 66C 6PF 702 7PT 7X7 8-0 8-1 8-3 8-4 8-5 8C1 8FI 8FJ 8UM 930 A01 A03 A8Z AAESR AAEVG AAHHS AAONW AAWTL AAZKR ABCQN ABEML ABIJN ABPVW ABUWG ACBWZ ACCFJ ACGFS ACMXC ACPRK ACSCC ACXQS ADBBV ADEOM ADIZJ ADKYN ADPDF ADZMN AEEZP AEIMD AENEX AEQDE AEUQT AFBPY AFKRA AFPWT AFZJQ AHMBA AIWBW AJBDE ALAGY ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR ASPBG ATUGU AVUZU AVWKF AZBYB AZFZN AZVAB BAFTC BBNVY BCNDV BDRZF BENPR BFHJK BHBCM BHPHI BMXJE BROTX BRXPI BY8 CCPQU CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DU5 DUUFO EBD EBS EJD EMOBN ESTFP F00 F01 F04 F1Z F5P FEDTE FUBAC FYUFA G-S G.N GNP GODZA GROUPED_DOAJ H.X HBH HCIFZ HF~ HHY HMCUK HVGLF HYE HZ~ IAO IHR IX1 J0M JPC KQQ LAW LC2 LC3 LH4 LITHE LOXES LP6 LP7 LUTES LW6 M65 M7P MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM N04 N05 N9A NF~ NNB O66 O9- OIG OK1 OVD OVEED P2P P2W P2X P2Z P4B P4D PALCI PIMPY PQQKQ Q.N Q11 QB0 QRW R.K RGB RIWAO RJQFR ROL RPM RWI RX1 SAMSI SUPJJ SV3 TEORI TWZ UB1 UKHRP V2E W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WIN WOHZO WQJ WRC WUP WVDHM WXI WXSBR XG1 XPP XV2 ~IA ~WT CGR CUY CVF ECM EIF ITC NPM AAYXX CITATION 3V. 7QP 7T5 7U9 7XB 8FE 8FH 8FK AZQEC DWQXO GNUQQ H94 K9. LK8 PQEST PQUKI PRINS 5PM |
ID | FETCH-LOGICAL-c4153-4c11f8d3e528a3354a8fd3e9763682e2ae3979618597008ff66fbe47f13d25683 |
IEDL.DBID | RPM |
ISSN | 0887-8013 |
IngestDate | Tue Sep 17 21:23:00 EDT 2024 Thu Oct 10 16:33:18 EDT 2024 Thu Sep 26 16:29:36 EDT 2024 Sat Sep 28 08:21:01 EDT 2024 Sat Aug 24 00:55:50 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | HDFN RhIG transfusion |
Language | English |
License | Attribution-NonCommercial-NoDerivs 2022 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4153-4c11f8d3e528a3354a8fd3e9763682e2ae3979618597008ff66fbe47f13d25683 |
ORCID | 0000-0003-3964-5466 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993642/ |
PMID | 35243688 |
PQID | 2648298573 |
PQPubID | 105667 |
PageCount | 5 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8993642 proquest_journals_2648298573 crossref_primary_10_1002_jcla_24323 pubmed_primary_35243688 wiley_primary_10_1002_jcla_24323_JCLA24323 |
PublicationCentury | 2000 |
PublicationDate | April 2022 |
PublicationDateYYYYMMDD | 2022-04-01 |
PublicationDate_xml | – month: 04 year: 2022 text: April 2022 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: New York – name: Hoboken |
PublicationTitle | Journal of clinical laboratory analysis |
PublicationTitleAlternate | J Clin Lab Anal |
PublicationYear | 2022 |
Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc |
Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc |
References | 1989; 34 1977; 49 1993; 53 2000; 40 2016; 30 2007; 92 2016; 110 2017 2011; 35 2009; 3 2008; 112 2018; 32 1998; 14 1999; 9 e_1_2_8_14_1 e_1_2_8_3_1 Cacciatore A (e_1_2_8_4_1) 2009; 3 Fung MK (e_1_2_8_15_1) 2017 e_1_2_8_2_1 e_1_2_8_5_1 e_1_2_8_7_1 e_1_2_8_6_1 Andres RL (e_1_2_8_13_1) 1989; 34 e_1_2_8_8_1 e_1_2_8_10_1 e_1_2_8_11_1 e_1_2_8_12_1 Scott JR (e_1_2_8_9_1) 1977; 49 |
References_xml | – volume: 32 start-page: 213 year: 2018 end-page: 219 article-title: Red blood cell alloimmunization in the pregnant patient publication-title: Transfus Med Rev – volume: 110 start-page: 51 year: 2016 end-page: 59 article-title: Interpretation of pretransfusion testing in obstetrical patients who have received antepartum Rh immunoglobulin prophylaxis publication-title: Vox Sang – volume: 112 start-page: 164 year: 2008 end-page: 176 article-title: Management of rhesus alloimmunization in pregnancy publication-title: Obstet Gynecol – volume: 14 start-page: 138 year: 1998 end-page: 140 article-title: Detection of anti‐D following antepartum injections of Rh immune globulin publication-title: Immunohematology – volume: 40 start-page: 1127 year: 2000 end-page: 1131 article-title: RBC antibody persistence publication-title: Transfusion – volume: 92 start-page: F83 year: 2007 end-page: F88 article-title: Haemolytic disease of the newborn publication-title: Arch Dis Child Fetal Neonatal Ed – volume: 35 start-page: 148 year: 2011 end-page: 154 article-title: Diagnostic laboratory technologies for the fetus and neonate with isoimmunization publication-title: Semin Perinatol – volume: 34 start-page: 318 year: 1989 end-page: 320 article-title: Elevated anti‐D titer after the administration of Rh immune globulin. A case report publication-title: J Reprod Med – volume: 9 start-page: 93 year: 1999 end-page: 97 article-title: Recommendations for the use of anti‐D immunoglobulin for Rh prophylaxis. British Blood Transfusion Society and the Royal College of Obstetricians and Gynaecologists publication-title: Transfus Med – volume: 49 start-page: 9 year: 1977 end-page: 14 article-title: Pathogenesis of Rh immunization in primigravidas. Fetomaternal versus maternofetal bleeding publication-title: Obstet Gynecol – volume: 53 start-page: 342 year: 1993 end-page: 345 article-title: [Antibody detection after antepartal rhesus prophylaxis: normal values or sensitization] publication-title: Geburtshilfe Frauenheilkd – year: 2017 – volume: 30 start-page: 159 year: 2016 end-page: 164 article-title: Hemolytic disease of the fetus and newborn: modern practice and future investigations publication-title: Transfus Med Rev – volume: 3 start-page: 25 year: 2009 end-page: 27 article-title: Obstetric management in Rh alloimmunizated pregnancy publication-title: J Prenat Med – ident: e_1_2_8_10_1 doi: 10.1016/j.tmrv.2018.07.002 – volume: 34 start-page: 318 year: 1989 ident: e_1_2_8_13_1 article-title: Elevated anti‐D titer after the administration of Rh immune globulin. A case report publication-title: J Reprod Med contributor: fullname: Andres RL – ident: e_1_2_8_5_1 doi: 10.1097/AOG.0b013e31817d453c – ident: e_1_2_8_2_1 doi: 10.1016/j.tmrv.2016.05.008 – ident: e_1_2_8_11_1 doi: 10.1053/j.semperi.2011.02.009 – volume-title: AABB Technical Manual, Nineteenth edition year: 2017 ident: e_1_2_8_15_1 contributor: fullname: Fung MK – ident: e_1_2_8_6_1 doi: 10.1111/vox.12302 – ident: e_1_2_8_3_1 doi: 10.1136/adc.2005.076794 – ident: e_1_2_8_14_1 doi: 10.1055/s-2007-1022894 – volume: 49 start-page: 9 year: 1977 ident: e_1_2_8_9_1 article-title: Pathogenesis of Rh immunization in primigravidas. Fetomaternal versus maternofetal bleeding publication-title: Obstet Gynecol contributor: fullname: Scott JR – ident: e_1_2_8_12_1 doi: 10.1046/j.1537-2995.2000.40091127.x – ident: e_1_2_8_8_1 doi: 10.1046/j.1365-3148.1999.009001093.x – ident: e_1_2_8_7_1 doi: 10.21307/immunohematology-2019-681 – volume: 3 start-page: 25 year: 2009 ident: e_1_2_8_4_1 article-title: Obstetric management in Rh alloimmunizated pregnancy publication-title: J Prenat Med contributor: fullname: Cacciatore A |
SSID | ssj0008916 |
Score | 2.3489773 |
Snippet | Background
Hemolytic disease of the fetus and newborn (HDFN) is a potentially fatal complication in Rh‐incompatible pregnancies and rarely occurs in the... Hemolytic disease of the fetus and newborn (HDFN) is a potentially fatal complication in Rh-incompatible pregnancies and rarely occurs in the sensitizing... Abstract Background Hemolytic disease of the fetus and newborn (HDFN) is a potentially fatal complication in Rh‐incompatible pregnancies and rarely occurs in... BackgroundHemolytic disease of the fetus and newborn (HDFN) is a potentially fatal complication in Rh‐incompatible pregnancies and rarely occurs in the... |
SourceID | pubmedcentral proquest crossref pubmed wiley |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | e24323 |
SubjectTerms | Agglutination Anemia Antibodies Antigens Blood banks Case Report Erythroblastosis, Fetal - diagnosis Female Fetus Fetuses HDFN Hemolytic disease Humans Infant, Newborn Medical records Obstetrics Patients Polyethylene glycol Pregnancy Retrospective Studies RhIG Rho(D) Immune Globulin transfusion Ultrasonic imaging Womens health |
SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1NT9wwEB21i4R6QbR8NC1FluCEFCC2kzgnxGe3CBBCIHGLnMQuQUt22QSttqf-hP7G_hLGjndhhcQtkS3L8otnnj2TNwCbyW6GPDxmflzwwucZy_xEyMQPpIgyGYYZs7k55xdR94af3oa37sKtdmmVE5toDXXRz80d-Y7JxKKJCGO2N3j0TdUoE111JTQ-whwNuAnTzh0cX1xeTW2xSGzxU7uV0BazqUAp3bnPe3KbckbZrEt6wzPfpku-prHWD50swoIjkGS_RfwzfFDVF5g_dyHyJRh31UO_N8ZW4oIvpK8J0jyiVfNUE1kVBKk0Ql-RsrINtUlib8o_6MXIYKh-Gw2OMRkhmgq7N-X_v_-OyEjWxCg5DI2J7I1JWbR5Rqog2HJ19-vnMtycHF8fdn1XX8HP0W0zn-dBoEXBVEiFZCzkUmh8Q4LCIkEVlcoE_SL06EmMS6l1FOlM8VgHrECmJNgKdKp-pb4CoUJEgczRWCjFKdUZZckujqRCESkRaA82JkucDloZjbQVTKapASK1QHiwNln91G2lOn0B3oPVFojpEMgejYK-8CCegWjawYhnz7ZU5Z0V0cZzJsOzlwdbFsx3ZpWeHp7t26dv78_vO3yi5ucIm9ezBp1m-KR-IGVpsnX3XT4DJuzr7w priority: 102 providerName: ProQuest – databaseName: Wiley Online Library - Core collection (SURFmarket) dbid: DR2 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1PT9swFH-qOKBd2GBjlAGytJ2QUoidP47EBQGloMEBDYnLFNmJTQMlrZpUVTnxEfYZ90l4dtKWgjSJ3RI9x3L8_vhn-_lngB_RvkQcHjInTL3U8SSTTsRF5LiCB1L4vmQ2N-fiMuhce-c3_k0DDqZnYSp-iNmCm_EMG6-NgwtZ7M1JQ--SnmhRj1FD9WmY9AwiuppzR_HI3ntqvQjDMJtxk9K9-aeLo9EbiPk2U_IlgrVDUPsj_J42vso8uW-NStlKHl_xOv7v332ClRqbksPKmFahofI1WL6od98_w6SjHvq9CUpJva9D-poggiRalaOCiDwliNLRqnKS5VZQmPz4MnvEAZIMhurW0HtMyBgNRWHxMvv79OeYjEVBDEnE0ETf3oRkaZXCpFKCkqvu2ekXuG6f_DrqOPXVDU6CiIA5XuK6mqdM-ZQLxnxPcI1viH1YwKmiQpn9xADBQhSiqrQOAi2VF2qXpQjCOFuHpbyfqw0glPPAFQnGIaU8SrWkLNrHmpTPA8Vd3YTvUxXGg4qhI664mGlsejG2vdiEral249pLi9hk99GI-yGKv1aKnlWBwNSQ8_MmhAsmMCtgeLkXJXnWtfzcOIVlOK1rwq7V8D9aFZ8f_Ty0T5vvKfwNPlBzCsMmEG3BUjkcqW3ERqXcsT7wDCqWC9Y priority: 102 providerName: Wiley-Blackwell |
Title | Hemolytic disease of the fetus and newborn in the sensitizing pregnancy where anti‐D was incorrectly identified as RhIG |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjcla.24323 https://www.ncbi.nlm.nih.gov/pubmed/35243688 https://www.proquest.com/docview/2648298573 https://pubmed.ncbi.nlm.nih.gov/PMC8993642 |
Volume | 36 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fa9swED-aDsZexv4vbRcE29PASS3JlvzYZe2yspQQVsibkWxp9UickLiU7GkfYZ9xn2Qn2Q4LhT3sRdickMWddPeT9dMJ4F1yqhGHCxaInOcB10wHiVRJECoZaxVFmnluzvgqHl3zy1k0O4CoPQvjSfuZLvrlfNEvixvPrVwtskHLExtMxkNcIzDEzYMOdARj7RK9cb8y8fed-tmD7pftcpLSwfdsrvqUM-puz0Hk4bKvy_2AdA9l3idL_g1ifRS6eAKPG_hIzupuPoUDUz6Dh-Nmg_w5bEdmsZxvUUqarReytARBHrGmut0QVeYEgTQaviRF6QUbR2Gvih8Yw8hqbb65DBxbcoe2NFi9Kn7__PWR3KkNcXkc1s5BzrekyGuWkckJSqY3nz-9gOuL86_DUdDcrhBkGLRZwLMwtDJnJqJSMRZxJS2-ITxBrVBDlXFbfjHG80SgVq2NY6sNFzZkOeIkyV7CYbkszWsgVMo4VBm6CmM4pVZTlpxiSyaSsZGh7cLbVsXpqk6ikdbpkmnqbJJ6m3ThpNV-2kykTeoIeDSRkUDxq9oQuyZaC3ZB7JloV8Glzt6X4IjyKbSbEdSF996Y_-hVejn8cuafjv77M8fwiLpTE57wcwKH1frWvEEsU-kedCifYClmAks5DHvw4MP51WTa838HXDmlPT_C_wB0svmI |
link.rule.ids | 230,315,733,786,790,870,891,1382,11589,12083,12250,21416,27955,27956,31752,33299,33777,43343,43612,43838,46085,46327,46509,46751,50847,50956,53825,53827,74100,74369,74657 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1NT9wwEB1RkNpeqtIv0vJhqT1VSiEeJ3FOFdoCC93lUIHELXISuwRts9tNENqe-hP6G_kljJ3s0hUSt0RjWZZfPPOceR4DfEr2MuLhMfpxIQpfZJj5iVSJHygZZSoMM3TanOFp1D8XJxfhRffDre5klXOf6Bx1Mc7tP_Jdq8TiiQxj_Dr57dtbo2x2tbtC4wmsCaRYbU-K9-4lHjJxV5-6hUSeGBflSfnuVT5SX7hAjssB6QHLfCiW_J_Euih0-BJedPSR7bd4r8OKrl7B02GXIH8Ns77-NR7NyMq61AsbG0YkjxndXNdMVQUjIk3AV6ysnKG2Evam_EMxjE2m-qetwDFjN4SlpuZNefv33zd2o2pm6zhMrYMczVhZtCojXTCy_Lg8PnoD54cHZ72-392u4OcUtNEXeRAYWaAOuVSIoVDS0BvRE4wk11xpm_KLKJ4nMU2lMVFkMi1iE2BBPEniW1itxpXeAMaljAKVk6vQWnBuMo7JHvWkQxlpGRgPPs6nOJ20RTTStlwyTy0QqQPCg8357KfdQqrTe9g9eNcCseiCuKOtny89iJcgWjSwpbOXLVV56Upo0y4TaeflwWcH5iOjSk96g3339P7x8e3As_7ZcJAOjk-_f4Dn3B6TcAqfTVhtptd6i8hLk227L_QOF8HtQQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NTtwwEB4BlRAX1B_ahtLWEj1VCkvsxHFOCC3dLr-qEEjcIiexIdWSXTZBaDnxCDxjn6Rjx7uwQuKWaCzL8oxnPme-zAD8SLYzxOEx8-MiLPwwY5mfCJn4gRQ8k1GUMcvNOT7h_fPw4CK6cPyn2tEqpz7ROupimJtv5B3DxKKJiGLW0Y4W8WevtzO68U0HKZNpde00FuENRkVuLFx0n-geIrFtUO2hQq_MZqVKaedvPpBbNGSUzQenF4jzJXHyOaC1Ean3FlYdlCS7re7fwYKq3sPysUuWf4BJX10PBxOUEpeGIUNNEPARrZrbmsiqIAiq0QgqUlZWUBs6e1PeYzwjo7G6NNU4JuQO9apweFP-e3jcI3eyJqamw9g4y8GElEXLOFIFQcnp1f7vNTjv_Trr9n3XacHPMYAzP8yDQIuCqYgKyVgUSqHxDaEK44IqKpVJ_3GM7UmMW6k15zpTYawDViBmEuwjLFXDSn0GQoXggczRbSgVUqozypJtnElFgisRaA82p1ucjtqCGmlbOpmmRhGpVYQHG9PdT92hqtMnE_DgU6uI2RSII00tfeFBPKei2QBTRnteUpVXtpw23jgZ3sI8-GmV-cqq0oPu0a59Wn99fd9hGY0zPdo_OfwCK9T8MWHJPhuw1Ixv1VfEMU32zRrofzqT8X8 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hemolytic+disease+of+the+fetus+and+newborn+in+the+sensitizing+pregnancy+where+anti%E2%80%90D+was+incorrectly+identified+as+RhIG&rft.jtitle=Journal+of+clinical+laboratory+analysis&rft.au=Walhof%2C+Mackenzie+L&rft.au=Leon%2C+Judith&rft.au=Greiner%2C+Andrea+L&rft.au=Scott%2C+James+R&rft.date=2022-04-01&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.issn=0887-8013&rft.eissn=1098-2825&rft.volume=36&rft.issue=4&rft_id=info:doi/10.1002%2Fjcla.24323&rft.externalDBID=HAS_PDF_LINK |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0887-8013&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0887-8013&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0887-8013&client=summon |